Sharemaestro Newsreel

J&J sees Spravato sales surge as psychedelic competitors loom

Johnson & Johnson's depression drug Spravato saw a 40% Q2 revenue increase, reaching $584 million, marking it as a key franchise with potential peak sales of $5 billion. While psychedelic treatments like Compass Pathways' COMP360 and Definium Therapeutics' DT120 show promising clinical results and …

Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion

Eli Lilly has announced an agreement to acquire AtaiBeckley, a mental-health-focused pharmaceutical company, for an initial sum of $2.8 billion. This deal, part of Eli Lilly's recent acquisition trend, involves paying $6.75 per share in cash, representing a 26% premium over AtaiBeckley's previous closing …

Grifols Trial Could Expand Treatment Options for 60,000 Patients

Grifols has initiated two new Phase 3 trials, SIGMA and XPERT, to expand the U.S. indications for its flagship immunoglobulins, GAMUNEX-C and XEMBIFY. The SIGMA trial focuses on preventing infections in hematologic cancer patients with secondary immunodeficiency, while XPERT aims to demonstrate XEMBIFY's non-inferiority …

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement …

Merck cholesterol drug, Lipfendra, approved by FDA (MRK:NYSE)

Merck's oral PCSK9 inhibitor, Lipfendra (enlicitide), has received FDA approval for adults with high cholesterol levels. The drug aims to reduce low-density lipoprotein cholesterol, commonly known as bad cholesterol. This approval provides a new treatment option for managing high cholesterol.

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly and Company is set to acquire AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, including treatment-resistant depression. The acquisition will expand Lilly's neuroscience pipeline, with AtaiBeckley's lead asset, BPL-003, already having U.S. FDA Breakthrough Therapy Designation and …

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck announced the FDA approval of LIPFENDRA (enlicitide) tablets, the first and only once-daily oral PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). This approval is based on results from the CORALreef Lipids and CORALreef HeFH Phase 3 …

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion to expand into psychedelic treatments for mental health disorders, a sector gaining interest with increased federal support. The deal, valued at $6.75 per share, gives Lilly access to AtaiBeckley's leading candidate, BPL-003, a psychedelic-based …

Merck's cholesterol pill gets US FDA approval

Merck has received U.S. FDA approval for its new cholesterol pill, Lipfendra (enlicitide), marking it as the first oral PCSK9 inhibitor to gain such regulatory clearance. This approval is a significant step for Merck in diversifying its portfolio beyond its successful cancer drug Keytruda, …

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Eli Lilly announced its acquisition of psychedelic drugmaker AtaiBeckley for $2.8 billion, aiming to expand its offerings in mental health treatments. This deal gives Lilly access to AtaiBeckley's experimental DMT-based drug, BPL-003, which is currently in Phase 3 clinical trials for treatment-resistant depression, with …

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

Shares of AtaiBeckley surged 50% premarket after a report indicated Eli Lilly was in talks to acquire the psychedelic drug developer this week. The potential deal could be worth over $2 billion, following an industry-wide rally spurred by a U.S. executive order aiming to …

Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?

AbbVie (ABBV) stock has achieved a 150.7% return over five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 46.4% due to strong cash flow and recent Tepkinly approval, market-based multiples, specifically the P/E …

Novo's Wegovy pill cleared for weight loss in EU

The European Commission has approved Novo Nordisk’s oral formulation of the weight-loss therapy Wegovy, making it the first oral GLP-1 agonist for obesity and overweight patients in the EU. This approval follows the drug's launch in the UK, UAE, and its existing presence in …

D.A. Davidson & CO. Trims Stake in Amgen Inc. $AMGN

D.A. Davidson & CO. reduced its stake in Amgen Inc. by 2.7% in the first quarter, selling 6,632 shares and retaining 241,522 shares valued at approximately $84.98 million. Amgen exceeded first-quarter earnings expectations, reporting an EPS of $5.15 on revenue of $8.62 billion, a …

Sanofi joins the mRNA vaccine patent wars

Sanofi has initiated lawsuits against Pfizer and Moderna, alleging infringement of its patents related to the delivery of messenger RNA using lipid nanoparticles in their COVID-19 and RSV vaccines. Acquired through the 2021 Translate Bio purchase, these patents represent Sanofi's strategy to gain value …

Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in Amgen Inc. by 2.9% in the first quarter, selling over 113,000 shares, though still holding 3.79 million shares valued at $1.33 billion. Amgen reported strong Q1 earnings, surpassing revenue and EPS expectations. Analyst sentiment …

Organon Suspends Earnings Calls While Sun Pharma Deal Is Pending

Is Biogen (BIIB) a Buy, Hold, or Sell Right Now

Biogen (BIIB) faces a complex market, balancing declining legacy revenue with promising new Alzheimer's and rare disease therapies. Despite a mixed analyst sentiment, recent upgrades and a significant potential upside to the consensus price target suggest cautious optimism. Investors should evaluate Biogen's strong valuation …

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson (NYSE: JNJ) experienced a nearly 10% stock pullback after its latest earnings report, which analysts view as a buying opportunity due to strong fundamentals and an outlook including revenue surpassing $100 billion. The company reported $25.31 billion in quarterly revenue and …

Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push

The article reports that Sanofi and Lilly are investing in AdvanCell's $315 million radiopharmaceutical initiative. This significant backing from major pharmaceutical companies highlights growing interest and investment in radiopharmaceutical development. The collaboration aims to advance AdvanCell's efforts in this specialized area of medicine.

Earnings Preview: Novartis AG to Report Financial Results on July 21

Novartis AG (NYSE:NVS) is scheduled to announce its quarterly earnings results on Friday, July 21st. The company has a history of meeting or beating analyst estimates and currently has a consensus EPS estimate of $1.76 and a revenue estimate of $13.56 billion for the …

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation plc (NASDAQ: AMRN) has announced that it will release its second quarter 2026 financial results and host a conference call on Wednesday, July 29, 2026. The company will issue a press release before market hours, followed by a call with senior management …

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV’s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer’s near-term cancer pipeline, the article notes that it doesn't fully mitigate the larger concerns of …

Samsung Bioepis and Organon Broaden Biosimilar Access in Australia

Samsung Bioepis and Organon have expanded their collaboration in Australia to include an additional biosimilar, deepening their existing partnership. This agreement grants Organon exclusive commercial rights for the new biosimilar in Australia, while Samsung Bioepis retains development, manufacturing, and regulatory responsibilities. The expansion aims …

(AMGN) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Amgen Inc. (NASDAQ: AMGN) stock, highlighting a weak near-term sentiment but strong long-term outlook. It details specific AI-generated trading strategies including long, breakout, and short positions with defined entry points, targets, and stop losses. The analysis also includes …

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

Novo Nordisk announced its ongoing Phase 3 clinical study, "Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity." This study investigates a new weekly injectable drug (NNC0487-0111) …

Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier

Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025. Mercier has …

Form 144 GILEAD SCIENCES For: 15 July By Investing.com

This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled

Bristol-Myers Squibb Co (BMY) stock rose 3.12% on July 15, driven by positive late-stage clinical trial results, increased institutional inflows into the defensive pharmaceutical sector, and favorable technical indicators. Despite facing patent expirations and pricing negotiation risks, the company's diversification strategy and pipeline successes …

Novartis stock holds steady on its global drug pipeline

Novartis's stock remains stable, supported by its global drug pipeline and status as a major European drugmaker. The company's focus on innovative medicines across oncology, immunology, cardiovascular disease, and neuroscience provides a strong foundation for its recurring specialty-drug revenue and resilience in the market. …

Johnson & Johnson commits to $55B, 4-year US investment plan

Johnson & Johnson's CFO Joe Wolk announced the company's commitment to a $55 billion, four-year investment plan in the US. Wolk discussed this plan, along with the company's Q2 earnings and the performance of its medical technology unit, including Impella heart pumps, during an …

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

Sanofi has initiated new patent infringement lawsuits against Pfizer and Moderna, targeting the lipid nanoparticle (LNP) technology used in their COVID-19 vaccines and Moderna's RSV vaccine. Sanofi claims the LNP tech, developed by its acquired Translate Bio, infringes on its patents related to mRNA …

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility

Johnson & Johnson reported a 6.6% revenue growth in the second quarter, driven by strong performances in Innovative Medicine and MedTech, leading management to increase 2026 guidance. While shares dropped 2% intraday, Morningstar is maintaining its $190 fair value estimate, noting J&J's robust oncology …

Novo gains head start on Lilly with European Commission approval of Wegovy pill

Novo Nordisk has secured a head start over Eli Lilly in Europe with the European Commission's marketing authorization for the Wegovy pill for obesity and overweight adults. This approval makes it the first GLP-1 receptor available in tablet form in Europe. The European Commission …

Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain

Johnson & Johnson is restructuring its pharmaceutical supply chain, announcing up to $750 million in costs to streamline operations, including offloading certain sites. This move follows a $55 billion commitment to bolster U.S. manufacturing capabilities for medicines in the U.S. The company reported strong …

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …